Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
What's Your Reaction?
